PerkinElmer enters into drug discovery collaboration

Skip to Navigation


  • Published: Jun 23, 2015
  • Author: Jon Evans
  • Source: PerkinElmer
  • Suppliers: PerkinElmer
  • Channels: Ion Chromatography / Sample Preparation / Gas Chromatography / Proteomics & Genomics / Laboratory Informatics / HPLC / Base Peak

PerkinElmer has entered into a drug discovery collaboration with Albany Molecular Research Inc. (AMRI), a US contract research and manufacturing company. This collaboration builds on the opening of AMRI's drug discovery center as part of the new Buffalo Medical Innovation and Commercialization Hub (BMIC), which aims to accelerate drug discovery and innovation.

Located within a single site on the Buffalo Niagara Medical Campus, AMRI will be working closely with BMIC and off-campus customers and partners to provide solutions for their drug discovery and translational science needs. Scientists at the BMIC hub will be able to leverage AMRI's chemistry and biology expertise, alongside PerkinElmer's informatics technologies and high content screening, cellular imaging and analytical instruments. PerkinElmer will also deploy technical and informatics experts to facilitate technological and drug discovery innovations. In addition, the collaboration will provide the foundation for new research and development opportunities and catalyze the expansion of the BMIC hub.

‘We are delighted to work together on this unique public-private endeavor with PerkinElmer, which is recognized in the industry for its leading drug discovery technologies and informatics platforms, that are critical for the success of AMRI's discovery and development businesses,’ said Michael Luther, senior vice president, discovery and development, at AMRI. ‘PerkinElmer's technologies will provide us with the ability to acquire, manage, integrate and analyze large complex data from the various translational platforms needed to drive better decisions in drug discovery. This will enable us to accelerate the knowledge and information our customers and partners need, and strengthen our end-to-end integrated discovery offerings.’

‘We are pleased to have the opportunity to deliver the platforms, informatics technologies and services to AMRI for its new center of excellence for drug discovery and translational research,’ said Jim Corbett, president, human health, at PerkinElmer. ‘We look forward to supporting the BMIC's expansion by working closely with additional companies that establish lab facilities at this site, providing scientists with solutions and services that will advance their research and lead them toward the next big breakthrough.’

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2018 John Wiley & Sons, Inc. All Rights Reserved